Market Cap
$198.8K
PPBT
PURPLE BIOTECH LTD.
$1.44 ▼ -5.26%
Prev close $1.52Market cap$198.8K
12-mo target$17.00 (+1080.6%)
High Impact Filing (7/10) Biotech & Drug Discovery
Snapshot
The big-picture read on PPBT right now — valuation, ownership and activity at a glance.
Cap Size
Nano Cap
Inst. Holders
9 funds
Inst. Value
$49.2K
Inst. Activity
2 buys / 2 sells
Social Sentiment
33° Cool
SEC Reports
7
Press Releases
2
Price chart 30d -27.3%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 29, 2026 reg_sho
Sep 9, 2026 SEC Reg SHO Threshold: PPBT exited the threshold list
PURPLE BIOTECH LTD SPONSORED A | On list since 2026-09-10
Purple Biotech Ltd. filed a 6-K on September 9, 2026, reporting the results of its Annual General Meeting of Shareholder
6-K — Impact 2/10
Purple Biotech announced a USPTO Notice of Allowance for a patent covering tri-specific antibody constructs and methods
6-K — Impact 3/10
Purple Biotech filed an updated corporate presentation on Form 6-K, highlighting its CAPTN-3 tri-specific antibody platf
6-K — Impact 4/10
Jun 30, 2026 Inst.
ROYAL BANK OF CANADA — DOUBLED
128 shares (—)
Jun 30, 2026 Inst.
Mar 13, 2026 Press SUSQUEHANNA INTERNATIONAL GROUP, LLP — NEAR_EXIT
12,847 shares ($21.6K)
Purple Biotech announced that CEO Gil Efron will step down in August 2026 due to health reasons but will remain on the B
Impact 3/10
Purple Biotech reported a significant net loss of $26.4 million for 2025, driven by a $20.5 million impairment charge re
Impact 6/10
Analyst ratings
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 7, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
Price targets
Where 1 covering analysts think PPBT trades over the next 12 months.
$17.00 +1080.6% upside Strong Buy
Current$1.44 Low$17.00 Median$17.00 High$17.00 1 analysts
$17.00$17.00
Analyst rating None as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
33°
Cool
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
7 SEC filing reports analyzed · 1 bullish, 0 bearish, 0 mixed, 6 neutral · avg impact 3.9/10.Plus 2 press releases.
NEUTRAL6-K2/10
Purple Biotech Ltd. filed a 6-K on September 9, 2026, reporting the results of its Annual General Me
Sep 9, 2026
NEUTRAL6-K3/10
Purple Biotech announced a USPTO Notice of Allowance for a patent covering tri-specific antibody con
Sep 2, 2026
NEUTRAL6-K4/10
Purple Biotech filed an updated corporate presentation on Form 6-K, highlighting its CAPTN-3 tri-spe
Aug 11, 2026
NEUTRAL6-K4/10
Purple Biotech reported Q2 2026 financial results with a net income of $0.4M driven by non-cash warr
Aug 7, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 29, 2026
reg_sho
Reg SHO Threshold: PPBT exited the threshold list
PURPLE BIOTECH LTD SPONSORED A | On list since 2026-09-10
Sep 10, 2026
reg_sho
Reg SHO Threshold: PPBT entered the threshold list
PURPLE BIOTECH LTD SPONSORED A | 5+ consecutive settlement days of fails-to-deliver ≥10k shares and ≥0.5% of shares outstanding
Sep 3, 2026
ftd
FTD: PPBT — 363,124 shares ($0.7M) failed to deliver
Settlement: 20260903, Price: $1.98, FTD Value: $718,985.52, PURPLE BIOTECH LTD SPONSORED A
Sep 2, 2026
short_volume
Short Volume: PPBT — 55.6% short (14.9M / 26.8M)
Short: 14,904,129 | Exempt: 3,858,515 | TRF Vol: 26,783,115 | Short Ratio: 55.6% | Off-exchange volume (dark pool + OTC)
Aug 7, 2026
earnings
Purple Biotech Reports Second Quarter 2026 Financial Results
New preclinical data presented at European Association for Cancer Research (EACR) 2026 Annual Congress, which further validates the differentiated pro
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-2.88 | $-2.88–$-2.88 | -199.3% | -66.5% | 0↑ 1↓ | $0.0B | 1 |
| Next Q | $-3.00 | $-3.00–$-3.00 | 51.3% | -19.5% | 0↑ 1↓ | $0.0B | 1 |
| Current FY | $-5.73 | $-5.73–$-5.73 | 30.4% | -7.9% | 0↑ 1↓ | $0.0B | 1 |
| Next FY | $-1.01 | $-1.01–$-1.01 | 82.4% | -14.8% | 0↑ 1↓ | $0.0B | 1 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-2.880 | — |
| 7d ago | $-1.730 | -1.150 |
| 30d ago | $-1.730 | -1.150 |
| 60d ago | $-1.730 | -1.150 |
| 90d ago | $-0.420 | -2.460 |
Institutional ownership
Which big funds own PPBT (from quarterly 13F filings) and who is adding or trimming.
9 institutional holders with $49.2K total value (44,046 shares) as of 2026-Q2. Top holders: ROYAL, CITADEL, SUSQUEHANNA.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| ROYAL BANK OF CANADA | 128 | $0.00 | 0.0% | DOUBLED +1180.0% |
| CITADEL ADVISORS LLC | 13,166 | $22.1K | 44.9% | — |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 12,847 | $21.6K | 43.9% | NEAR_EXIT -75.9% |
| Arax Advisory Partners | 1,453 | $2.4K | 5.0% | — |
| RHUMBLINE ADVISERS | 856 | $1.4K | 2.9% | — |
| UBS Group AG | 751 | $1.3K | 2.6% | DOUBLED +658.6% |
| MORGAN STANLEY | 197 | $331.00 | 0.7% | TRIM -65.9% |
| HRT FINANCIAL LP | 14,640 | $24.00 | 0.0% | — |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 8 | $13.00 | 0.0% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| ROYAL BANK OF CANADA | DOUBLED | 10 | 128 | +1180.0% | — |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | NEAR_EXIT | 53,403 | 12,847 | -75.9% | $21.6K |
| UBS Group AG | DOUBLED | 99 | 751 | +658.6% | $1.3K |
| MORGAN STANLEY | TRIM | 578 | 197 | -65.9% | $331.00 |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for PPBT.
Shares short
80,940
Settlement Sep 15, 2026
Change vs prior
+187.8%
Semi-monthly cycle
Days to cover
1.0
At avg daily volume
Of shares outstanding
≈5.0%
Estimate — not % of float
All PPBT filing & press-release reports (9)
- 6-K reportSep 9, 2026
- 6-K reportSep 2, 2026
- 6-K reportAug 11, 2026
- 6-K reportAug 7, 2026
- PRESS-RELEASE reportMay 15, 2026
- 6-K reportApr 27, 2026
- 6-K reportApr 23, 2026
- PRESS-RELEASE reportMar 13, 2026
- PRESS-RELEASE reportMar 13, 2026